Completado

IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

cytarabine

+ daunorubicin hydrochloride

+ dexamethasone

MedicamentoProcedimientoRadiación
Quiénes están siendo reclutados

Anemia+12

+ Anemia Refractaria

+ Enfermedades de la Médula Ósea

Hasta 14 Años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Tratamiento

Fase 3
Intervencional
Inicio del estudio: marzo de 1993
Ver detalles del protocolo

Resumen

Patrocinador PrincipalEuropean Organisation for Research and Treatment of Cancer - EORTC
Última actualización: 22 de junio de 2010
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de marzo de 1993

Fecha en la que se inscribió al primer participante.

OBJECTIVES: Compare the efficacy of idarubicin vs mitoxantrone in induction and first intensification in terms of achieving and maintaining complete remissions in children with acute myeloid leukemia or myelodysplastic syndrome. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center and disease type (de novo acute myeloid leukemia (AML) vs AML secondary to myelodysplastic syndrome (MDS) vs MDS). Induction: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive cytarabine (ARA-C) IV continuously on days 1 and 2 and then IV over 30 minutes every 12 hours on days 3-8, mitoxantrone IV on days 3-5, etoposide (VP-16) IV over 1 hour on days 6-8, and ARA-C intrathecally (IT) on days 1 and 8. Arm II: Patients receive ARA-C and VP-16 as in arm I and idarubicin IV on days 3-5. Patients on both arms with CNS disease at presentation receive ARA-C IT every 3 days until the CSF clears and then weekly until the first intensification. After induction, patients on both arms proceed to first intensification, regardless of response. First intensification: When blood counts recover and within 40 days after initiating induction, patients are randomized to 1 of 2 treatment arms. Arm III: Patients receive high-dose ARA-C IV over 3 hours every 12 hours on days 1-3 (if allogeneic bone marrow transplantation (BMT) is planned) or days 1-4 (if allogeneic BMT is not planned) and mitoxantrone IV on days 7-9. Arm IV: Patients receive high-dose ARA-C as in arm III and idarubicin IV on days 7-9. Patients who achieve complete remission (CR) after first intensification and have an HLA-identical, chronic myelomonocytic leukemia-nonreactive, sibling donor undergo allogeneic BMT. Patients who achieve CR after intensification and have no suitable donor receive intensive chemotherapy as defined below. All patients with chloroma at presentation undergo local radiotherapy beginning after final intensification. Second intensification: When blood counts recover, patients receive daunorubicin IV continuously, ARA-C IV continuously, VP-16 IV continuously, oral thioguanine, and oral dexamethasone on days 1-4 and 11-14 and ARA-C IT on days 1, 4, 11, and 14. Third intensification: When blood counts recover, patients receive high-dose ARA-C IV over 3 hours every 12 hours on days 1-3 and VP-16 IV over 1 hour on days 2-5. When blood counts recover, autologous bone marrow is harvested in the event of subsequent relapse. Maintenance: When blood counts recover, patients receive oral thioguanine daily and ARA-C subcutaneously 4 days a month for 1 year. PROJECTED ACCRUAL: A total of 310 patients will be accrued for this study within 5 years.

NCT00002517
Patrocinador PrincipalEuropean Organisation for Research and Treatment of Cancer - EORTC
Última actualización: 22 de junio de 2010
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.

Estudio de Tratamiento

Estos estudios prueban nuevas formas de tratar una enfermedad, condición o problema de salud. El objetivo es determinar si un nuevo medicamento, terapia o enfoque funciona mejor o tiene menos efectos secundarios que las opciones existentes.

Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

Hasta 14 Años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

AnemiaAnemia RefractariaEnfermedades de la Médula ÓseaEnfermedad CrónicaEnfermedades HematológicasEnfermedades hemáticas y linfáticasLeucemia MieloideNeoplasiasNeoplasias por tipo histológicoProcesos PatológicosCondiciones Patológicas, Signos y SíntomasAnemia Refractaria con Exceso de BlastosLeucemiaSíndromes MielodisplásicosLeucemia Mielomonocítica Crónica

Criterios

DISEASE CHARACTERISTICS: Newly diagnosed acute myeloid leukemia (AML) based on the cytological, cytochemical, and immunological criteria of the FAB classification Must meet 1 of the following criteria: More than 30% blasts in marrow (calculation based on the total number of nucleated cells except lymphocytes and plasmocytes) Presence of granulocytic sarcoma (chloroma) Disease must be associated with at least 1 of the following: More than 3% myeloperoxidase- or Sudan black-positive blasts More than 3% platelet peroxidase-positive blasts More than 20% esterase-positive blasts Immunological markers compatible with a myeloid differentiation, including 1 of the following criteria: Blasts positive for myeloid-associated antigen and negative for B- or T-lymphocyte antigens Blasts positive for at least 2 myeloid antigens (except CD3 and CD8) A cytogenetic abnormality associated with AML OR Newly diagnosed myelodysplastic syndrome (MDS) based on the cytological and cytochemical criteria of the FAB classification Eligible subtypes: Refractory anemia with excess blasts (RAEB) RAEB in transformation Chronic myelomonocytic leukemia No promyelocytic leukemia (M3 or M3v) treated with tretinoin (protocol EORTC-06915) No AML secondary to hematologic or malignant disease other than MDS Registration must occur within 48 hours of diagnosis PATIENT CHARACTERISTICS: Age: Under 15 Performance status: Not specified Life expectancy: Not specified Hematopoietic: See Disease Characteristics No uncontrolled bleeding disorder Hepatic: Not specified Renal: No renal failure Cardiovascular: No congenital heart disease Other: No encephalopathy No genetic disorders No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior antileukemic therapy

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 23 ubicaciones

Algemeen Ziekenhuis Middelheim

Antwerp, BelgiumAbrir Algemeen Ziekenhuis Middelheim en Google Maps

Hopital Universitaire Des Enfants Reine Fabiola

Brussels, Belgium

Academisch Ziekenhuis der Vrije Universiteit Brussel

Brussels, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium
Completado23 Centros de Estudio